verubecestat   Click here for help

GtoPdb Ligand ID: 8699

Synonyms: example 25 (US8940748) | MK-8931
PDB Ligand
Compound class: Synthetic organic
Comment: This is a new INN/USAN for a Merck BACE1 inhibitor for clinical trials in Alzheimer's disease (AD). Despite some early confusion surrounding the relationship between MK-8931, SCH 900931 and verubecestat, the article published by Scott et al. (2016) formally acknowledges verubecestat as MK-8931 [4].
Despite reaching Phase 3 clinical trial, Merck has announced (Feb 2017: Merck press release) termination of study NCT01739348 (in patients with mild-moderate AD) because they concluded there was no chance of achieving efficacy. This is the latest of a long list of BACE1 inhibitors to fail in AD. Papers reporting trial outcomes were published in May 2018 [1] and April 2019 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 126.13
Molecular weight 409.1
XLogP 1.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(nc1)C(=O)Nc1ccc(c(c1)C1(C)N=C(N)N(S(=O)(=O)C1)C)F
Isomeric SMILES Fc1ccc(nc1)C(=O)Nc1ccc(c(c1)[C@@]1(C)N=C(N)N(S(=O)(=O)C1)C)F
InChI InChI=1S/C17H17F2N5O3S/c1-17(9-28(26,27)24(2)16(20)23-17)12-7-11(4-5-13(12)19)22-15(25)14-6-3-10(18)8-21-14/h3-8H,9H2,1-2H3,(H2,20,23)(H,22,25)/t17-/m0/s1
InChI Key YHYKUSGACIYRML-KRWDZBQOSA-N
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
beta-secretase 2 Hs Inhibitor Inhibition 9.4 – 9.9 pKi - 3,5
pKi 9.9 (Ki 1.2x10-10 M) [5]
Description: BInding affinity determined in a competitive radioligand binding assay using the nonselective BACE1/2 inhibitor [3H] JNJ-962
pKi 9.4 (Ki 3.7x10-10 M) [3]
beta-secretase 1 Hs Inhibitor Competitive 8.8 – 9.5 pKi - 3,5
pKi 9.5 (Ki 3.4x10-10 M) [5]
Description: BInding affinity determined in a competitive radioligand binding assay using the nonselective BACE1/2 inhibitor [3H] JNJ-962
pKi 8.8 (Ki 1.753x10-9 M) [3]